Rapid Growth Through Vertical Integration

Lupin entered the U.S. generic pharmaceutical market in 2003 with ANDA approval for Cefuroxime Axetil Tablets. We have since received more than 250 FDA approvals and market a total of 180 generic products. This has solidified us as one of the fastest-growing pharmaceutical companies in the U.S. Our consistent track record of growth on the generic side is a result of a robust pipeline, strong customer relationships, and flawless execution.

We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time—and the right price. Because our manufacturing is also integrated, we are able to closely monitor the integrity of our generic products, a competitive advantage in an industry where customer trust and safety are non-negotiable.



Lupin’s generic business is geared to expand even further with plans to launch new products and expand its pipeline to offer medications in new therapeutic areas such as Dermatology, Pediatrics, Women’s Health, Inhalation and Complex Injectables.

The rapid pace of our generic growth is possible, in part, thanks to our globally integrated network of 18 manufacturing facilities. These world class facilities are built to manufacture and deliver a wide range of finished products to the U.S. market. All facilities are committed to compliance with quality, safety and environmental standards.

pills in shape of lightbulb